Brind.

ALK-Abelló partnered with ARS Pharma outside the U.S. on July 18, 2025, and gained rights to market EURneffy in the U.K.

2 reports, 2 independent Updated Jun 22
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

ALK-Abelló partnered with ARS Pharma outside the U.S. on July 18, 2025, and gained rights to market EURneffy in the U.K.

Who's involved

What this event is mainly about
ALK-Abelló

How it developed

Newest first. Tap a step to see who reported it.
  1. ALK-Abelló's EURneffy received marketing authorisation from the MHRA.1 source
  2. ALK-Abelló partnered with ARS Pharma outside the U.S. on July 18, 2025.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • nursinginpractice.com
  • GlobeNewswireEURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) EURneffy (neffy® in the U.S.) offers a new delivery m